Onco Targets Ther 2018
The predictive ability of plasma ESR1 mutations for the efficacy of endocrine therapy in hormone-receptor-positive advanced breast cancer.
Related Questions
New answer by Medical Oncologist at Memorial Sloan Kettering Cancer Center (November 22, 2019)
I would test if I was considering single agent hormone therapy. I agree with the points raised in @Adam L. Cohen excellent and thorough answer. I would add that the detec...